Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fcvm.2025.1602666 http://scihub22266oqcxt.onion/10.3389/fcvm.2025.1602666 C12583036!12583036 !41195123     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41195123 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Front+Cardiovasc+Med 2025 ; 12 (?): 1602666 Nephropedia Template TP {{tp|p=41195123 |t=2025. Protocol for a randomized controlled trial of Xueshuantong injection on myocardial injury and residual cardiovascular risk in patients with unstable angina |pdf=|usr=}}{{41195123 }} gab.com Text Protocol for a randomized controlled trial of Xueshuantong injection on myocardial injury and residual cardiovascular risk in patients with unstable angina JO: Front Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=41195123 #FOAvip BACKGROUND: Unstable angina (UA) is a critical subtype of acute coronary syndrome (ACS). Myocardial injury is a key determinant of disease progression and long-term prognosis, yet it often persists despite standard therapy. In addition, residual inflammation remains an important risk factor for adverse outcomes. Xueshuantong Injection Lyophilized (XST), derived from Panax notoginseng saponins (PNS), has shown potential to reduce myocardial injury and modulate inflammatory responses in cardiovascular disease, but its efficacy in UA has not been fully evaluated. METHODS: This is a randomized, parallel control, double-blind, small-sample exploratory clinical trail. Participants will be recruited from Xiyuan Hospital, China Academy of Chinese Medical Sciences (Beijing, China). Eligible patients with UA will be randomized into two groups. The intervention group will receive XST 500?mg intravenously once daily for 7 days, and the control group will receive XST 25?mg intravenously once daily for 7 days. The primary outcome is CK-MB at Day 7. Secondary outcomes are cTnT, NT-proBNP, inflammatory/endothelial biomarkers (hs-CRP, IL-6, MMP-9, VEGF, HMGB1), and angina-related parameters (attack frequency, symptom severity). ETHICS AND REGISTRATION: The trial has been approved by the Ethics Committee of Xiyuan Hospital and registered in the ITMCTR on March 21, 2025, http://itmctr.ccebtcm.org.cn (No. ITMCTR2025000552). CONCLUSION: This exploratory study will evaluate the efficacy and safety of XST in reducing myocardial injury and residual risk in UA patients, providing evidence for future large-scale confirmatory trials. Twit Text FOAVip Protocol for a randomized controlled trial of Xueshuantong injection on myocardial injury and residual cardiovascular risk in patients with unstable angina ????Front Cardiovasc Med http://www.kidney.de/pget.php?&tw=1&pmid=41195123 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41195123 #FOAvip English Wikipedia <ref>{{Cite pmid|41195123 }}</ref> Protocol for a randomized controlled trial of Xueshuantong injection on myocardial injury and residual cardiovascular risk in patients with unstable angina #MMPMID41195123 Wang Y ; Liu G ; Lu Z ; Xi J ; Feng W ; Ma Y ; Lyu J ; Xie Y Front Cardiovasc Med 2025[]; 12 (?): 1602666 PMID41195123 show ga BACKGROUND: Unstable angina (UA) is a critical subtype of acute coronary syndrome (ACS). Myocardial injury is a key determinant of disease progression and long-term prognosis, yet it often persists despite standard therapy. In addition, residual inflammation remains an important risk factor for adverse outcomes. Xueshuantong Injection Lyophilized (XST), derived from Panax notoginseng saponins (PNS), has shown potential to reduce myocardial injury and modulate inflammatory responses in cardiovascular disease, but its efficacy in UA has not been fully evaluated. METHODS: This is a randomized, parallel control, double-blind, small-sample exploratory clinical trail. Participants will be recruited from Xiyuan Hospital, China Academy of Chinese Medical Sciences (Beijing, China). Eligible patients with UA will be randomized into two groups. The intervention group will receive XST 500?mg intravenously once daily for 7 days, and the control group will receive XST 25?mg intravenously once daily for 7 days. The primary outcome is CK-MB at Day 7. Secondary outcomes are cTnT, NT-proBNP, inflammatory/endothelial biomarkers (hs-CRP, IL-6, MMP-9, VEGF, HMGB1), and angina-related parameters (attack frequency, symptom severity). ETHICS AND REGISTRATION: The trial has been approved by the Ethics Committee of Xiyuan Hospital and registered in the ITMCTR on March 21, 2025, http://itmctr.ccebtcm.org.cn (No. ITMCTR2025000552). CONCLUSION: This exploratory study will evaluate the efficacy and safety of XST in reducing myocardial injury and residual risk in UA patients, providing evidence for future large-scale confirmatory trials. ?Protocol for a randomized controlled trial of Xueshuantong injection o(epmc).pdf DeepDyve Pubget Overpricing